Table 1.
MiR-223 in diseases with bone disorders.
| Disease | MiR-223 Expression | Target Gene | Species | MiR-223 Effect | Reference |
|---|---|---|---|---|---|
| Rheumatoid arthritis (RA) | ↑ (21.0 ± 14.4-fold) | NFIA | Human | Accompany by acutely severe synovitis and poorly controlled bone destruction | [33,34,43] |
| Osteoarthritis (OA) | ↑ (4.1 ± 3.1-fold) | NFIA | Human | Not mentioned | [33,34,43] |
| Collagen-induced arthritis (CIA) | ↑ (29-fold) on day 21 after collagen immunization | NFIA | Mouse | Accompany with reduction of NFIA and elevation of M-CSFR | [33,43] |
| Osteopetrosis | ↓ | NFIA | Mouse | Down-regulation of osteoclast differentiation | [43] |
| Osteosarcoma | ↓ | ECT2 HSP90B1 | Human | Correlated with high tumor grade, the presence of tumor metastasis and recurrence, and the poor response to chemotherapy and also predicted a decreased survival prediction of patients | [75,76,77,85] |
| Multiple myeloma | ↑ | Human | Not mentioned | [78,79] | |
| Vascular calcification | ↑ | RHOB, MEF2C | Human | Promotion of VSMC proliferation and migration | [81,86] |
| Chronic kidney disease-mineral and bone disorder (CKD-MBD) | ↓ | NFIA RHOB | Human | Obliterate the inhibitory effects of inorganic phosphate on osteoclastogenesis | [49] |